Navigation Links
Sensible Medical Innovations Closes on Financing Round Led by Boston Scientific Corporation

Kfar Neter, Israel (PRWEB) November 11, 2013

Sensible Medical Innovations (Sensible), the developer of a non-invasive thoracic fluid status monitor, today announced the closing of its latest round of funding. The round was led by Boston Scientific Corporation (NYSE: BSX) and joined by Shanghai LongTec Medical Technology Co., Ltd. and current investors SCP Vitalife and Genesis Partners. Proceeds are intended to be used for further collection of clinical data and global product commercialization.

Sensible’s disruptive, non-invasive technology provides a quantitative absolute measurement of lung fluid content and is intended for patients with fluid management problems such as patients living with heart failure, patients taking diuretic medication, recovering from a coronary artery disease related event or living with end stage renal disease.

The Sensible solution is designed to enable patients and physicians to monitor patients’ lung fluid more precisely than the weight- and symptoms-based monitoring used today. In addition, the non-invasive, wearable device does not require patients to undergo the surgery required with more invasive implantable hemodynamic monitors. Effective lung fluid status management is intended to improve the quality of care while reducing the overall cost related to hospitalizations.

“Having worked with Sensible for the past few years, I am impressed with the data demonstrating the technology’s performance, accuracy and robustness,” said Professor William T. Abraham, Director of Cardiovascular Medicine at The Ohio State University Wexner Medical Center and Chairman of Sensible’s Physician Steering Committee. “The need for an absolute measurement of lung fluid is critical and will enable us to take better care of our patients.”

“Current data provide promising evidence that the device can be used as an effective tool to improve patient care and outcomes in a disease that still has high mortality rates and significant costs to society,” said Professor Stefan Anker, President of the Heart Failure Association of the European Society of Cardiology and a member of Sensible’s Physician Steering Committee. “This non-invasive technology appears well suited for medical needs in Europe.”

“We are humbled and excited to join forces with our new investors whose funding will help bring the company to the next level,” said Amir Ronen, CEO of Sensible. “We are proud that our technology has been embraced by leading physicians worldwide who are helping us in our path towards commercialization. A robust and accurate technology for non-invasive fluid monitoring is clearly a dramatic and disruptive capability that could impact the lives of millions.”

About Sensible Medical Innovations
Sensible has developed a wearable thoracic fluid status monitor for non-invasive monitoring and management of patients with fluid management problems such as patients living with heart failure, taking diuretic medication, recovering from a coronary artery disease related event and patients living with end stage renal disease. The company, headquartered in Kfar Neter, Israel was founded in 2007, by Amir Ronen, Amir Saroka, Dan Rappaport, Nadav Mizrahi and Shlomi Bergida.

Media Contact
Ido Atiya
Tell: + 972-3-6880908
Cell: +972-54-4289205

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinverse, Inc. Hosting Complimentary Webinar on Sensible Clinical Trial Management
2. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
3. DiaTech Life Sciences Announces Medical Advisory Board
4. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
5. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
6. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
7. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
10. Live Press Briefing on Findings of Biomedical Industry CEO Survey
11. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
Post Your Comments:
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Global Stem ... development stages of a new closed system for isolating adipose-derived stem cells. The announcement ... fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care hub ... northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. , ... cell medicine to patients from around the world. , The clinics will be headed by ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):